Articles tagged with Prostate Cancer
Researchers engineered supercharged T cells that can recognize and kill prostate cancer cells more effectively. By fine-tuning how they physically interact with tumor cells, the T cells form a stronger bond, allowing them to deliver a targeted immune response without damaging healthy tissue.
Researchers compare prostate cancer screening to breast cancer screening, finding similarities in identifying significant cancers and reducing mortality. The study suggests that prostate cancer screening should be reconsidered, offering benefits over harms, and highlights the need for further analysis on costs.
A new imaging test, PSMA PET/CT scan, has been shown to safely reduce the number of biopsies needed for suspected prostate cancer, with no harm to patients. The PRIMARY2 trial found that the scan could identify low-risk patients who did not need a biopsy, while targeting suspicious areas for those who did.
The Sylvester Cancer Tip Sheet for March 2026 highlights the importance of genetic testing for cancer risk assessment. Researchers have made significant progress in developing new treatments, including mRNA-based immunotherapy for colorectal and pancreatic cancers. Additionally, the Dolphins Cancer Challenge has surpassed $100 million ...
Research presented at EAU26 confirms that prostate cancer screening leads to a reduction in mortality, but also detects cancers that would otherwise remain undetected. The study's findings suggest that using MRI in prostate cancer screening can reduce overdiagnosis and unnecessary biopsies.
A new study found that MYC amplification in metastatic prostate cancer is associated with reduced tumor immunogenicity, making it harder for the immune system to detect and attack the tumor. This reduction in immunogenicity was linked to poorer progression-free survival outcomes in patients with MYC-amplified tumors.
A study by the University of Texas M. D. Anderson Cancer Center found that men with low testosterone levels are 60% more likely to have their prostate cancer progress to a more aggressive state during surveillance. Low testosterone may serve as a useful clinical marker to guide treatment and surveillance strategies.
Researchers at Weill Cornell Medicine have identified the FOXJ1 gene as a key player in chemotherapy resistance in prostate cancer. The study found that increased FOXJ1 levels in tumors can make cancer cells less responsive to taxane chemotherapy, leading to poorer outcomes for patients.
A study of 2,997 adults with advanced prostate cancer taking androgen-receptor pathway inhibitors and anticoagulants found no increased risks of bleeding or clotting. The findings contradict previous lab results and provide reassurance for clinicians and patients managing anticoagulation alongside modern prostate cancer treatments.
Researchers at Weill Cornell Medicine will develop an AI system to identify patients with early signs of treatment-resistant prostate cancer. The project aims to improve clinical trials by predicting treatment outcomes and avoiding ineffective treatments for patients with specific tumor subtypes.
Researchers found that tumors with androgen receptor alterations experienced poorer outcomes, shorter overall survival, and earlier need for subsequent therapy. Serial liquid biopsies revealed real-time molecular changes linked to treatment pressure.
Researchers developed a new immunotherapy strategy by pairing next-generation therapy with standard hormone therapy before surgery, reducing Treg levels inside tumors and improving patient outcomes. The study provides clinical evidence for the effectiveness of engineered anti-CTLA-4 therapies in early-stage prostate cancer treatment.
A new UCLA study suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with low PSA levels. However, men with higher PSA levels before radiation may see modest improvements in survival and metastasis-free survival.
The European Association of Nuclear Medicine (EANM) has launched a new award to accelerate alpha radioligand therapy (α-RLT) research in prostate cancer. The EANM Young Scientist Network Award offers €40,000 in funding for promising researchers.
A new study has discovered microplastics in nine out of ten patients with prostate cancer, with higher levels found in tumor tissue than noncancerous tissue. The findings suggest that microplastic exposure may be a risk factor for prostate cancer.
Researchers found that radiation-resistant cancer cells are vulnerable to NK cell-mediated killing due to increased expression of specific cellular membrane proteins, creating an 'evolutionary double-bind'. The combination of radiation therapy and NK cell-based immunotherapy was more effective in suppressing both sensitive and resistan...
Researchers found patients who retreated with docetaxel had longer overall survival and fewer supportive-care needs compared to those switching to cabazitaxel. The study provides evidence-based options for selected patients previously tolerated docetaxel.
Studies presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium highlight the growing potential of RPTs to improve cancer outcomes. A meta-analysis shows Lu-177 PSMA-617 consistently prolongs progression-free survival without adding severe side effects for patients with advanced prostate cancer.
A medication commonly used to treat overactive bladder significantly reduced hot flashes in men receiving hormone therapy for prostate cancer. Men who took oxybutynin also reported improvements in day-to-day functioning and overall quality of life.
Researchers identified a gene expression signature and inflammation patterns in normal tissue near the tumor to distinguish between patients with aggressive disease. The study paves the way for early identification of high-risk patients through blood or semen samples.
Researchers found that PSMA PET/CT scans can help guide treatment planning and improve long-term outcomes for patients with recurring prostate cancer. The study suggests that incorporating these scans into routine care may lead to better results and reduced side effects.
A new study reveals the CDK12-FOXA1-MDM2-p53 signaling axis promotes prostate cancer development through FOXA1 modification. The study identifies S234 phosphorylation as a critical site, and a CDK12 inhibitor THZ531 effectively blocks this pathway, reducing tumor growth.
A new AI-powered analysis tool called PROVIZ is being tested in Norwegian hospitals to diagnose prostate cancer. The tool helps doctors determine which patients need a biopsy, reducing the number of unnecessary procedures.
A meta-analysis of individual patients with oligometastatic prostate cancer shows that metastasis-directed radiation therapy (MDT) significantly improves patient outcomes, including delayed disease progression and better quality of life. The study included 574 men and found a median of 7.6 months before disease progression in the MDT a...
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
A review decodes the comprehensive role of GDF15 in prostate cancer metabolism, chemoresistance, and clinical applications, highlighting its involvement in cachexia, bone metastasis, and drug resistance. The study also explores the synergistic power of combining GDF15 with established markers for improved diagnosis and prognosis.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
A clinical trial has shown that a novel cooled laser focal therapy device can effectively treat prostate cancer with minimal side effects. The treatment provided similar cancer-related outcomes to traditional methods but with an improved safety profile and low rates of incontinence.
A phase 2 clinical trial is comparing three strategies to protect heart health in prostate cancer patients undergoing hormone therapy. The study will assess the impact of intermittent fasting, GLP-1 medication, and nutritional counseling on cardiovascular and metabolic risks associated with androgen deprivation therapy.
Researchers summarize the role of metabolic reprogramming in driving prostate cancer progression, highlighting key regulators and inter-pathway crosstalk mechanisms. Novel targeted therapeutic strategies targeting glucose, glutamine, and lipid metabolism are proposed to overcome current treatment bottlenecks.
The report shows a notable increase in medication treatments, such as chemotherapy, immunotherapy, and hormone therapy, used before surgery to treat many cancers. Neoadjuvant systemic therapy increased notably for certain cancers, including gynecologic cancers, pancreatic cancer, and rarer abdominal lining cancers.
Scientists at Northwestern University have determined the three-dimensional structures of rye pollen's cancer-fighting molecules, secalosides A and B. This breakthrough opens the door to exploring how these molecules interact with the immune system and could inspire new approaches to cancer therapy.
Researchers at VCU Massey Comprehensive Cancer Center and VCU Institute of Molecular Medicine are developing a novel therapy using engineered immune cells to target advanced prostate cancer. The therapy, which uses genetically modified natural killer cells producing the IL-24S 'Superkine', has shown promise in early-stage studies.
Predictions for lung cancer death rates among EU and UK women indicate stabilization of mortality rates at 12.5 deaths per 100,000 in 2026. Lung cancer remains the leading cause of cancer death for both sexes in the EU, with mortality rates continuing to decline among men.
The Phase 2 ANDROMEDA trial combines two types of PSMA-targeted radiopharmaceuticals with stereotactic body radiotherapy to delay progression and minimize side effects in patients with oligorecurrent prostate cancer. Researchers aim to determine which approach provides the most durable cancer control.
A major U.S. clinical trial has uncovered a genetic factor that may inform how to optimize the dosing of abiraterone, a widely used hormone treatment for advanced prostate cancer. Researchers found that men who carry a specific version of the gene SULT2A1 clear abiraterone from their bodies more slowly, which could affect how well it w...
Researchers from University Hospitals Seidman Cancer Center found that the optimal duration of hormone therapy for prostate cancer treatment varies by disease risk. For high-risk patients, longer courses of ADT provide diminishing benefits while increasing the risk of non-prostate cancer death.
A new long-term prediction tool estimates the risk of dying from prostate cancer by combining PSA levels with factors like family history, race, age, and other health conditions. The tool showed higher accuracy in predicting prostate cancer death over decades compared to existing models.
A new study from Mayo Clinic introduces MedEduChat, an EHR-integrated AI agent providing accurate and patient-specific prostate cancer education. The tool delivers clear explanations based on each patient's health record, improving confidence and understanding of diagnosis and treatment options.
A new clinical trial, RECIPROCAL, seeks to optimize targeted radiation therapy for men with advanced prostate cancer by adjusting treatment based on individual PSA levels. The trial aims to minimize side effects while preserving survival benefits.
A new study found that a widely used genomic test can accurately identify African American men with early prostate cancer at high risk of recurrence. The Decipher classifier linked to faster recurrence rates and supports more personalized treatment choices. Genomic testing may help better match patients with the right treatment intensi...
Daily scans taken during prostate cancer radiotherapy can identify changes linked to future rectal bleeding as early as one week into treatment. This allows doctors to adapt radiotherapy to limit side effects while maintaining cancer control.
A study published in JAMA Oncology found that shorter courses of androgen deprivation therapy can effectively control prostate cancer without increasing risks. The ideal duration of ADT depends on cancer risk, allowing for more personalized treatment plans.
Researchers identified a mechanism driving neuroendocrine prostate cancer and developed a dual-drug treatment that slowed tumor growth in lab tests. The findings highlight ERRγ as a promising new therapeutic target for patients with limited treatment options.
The new department will drive the next generation of discovery and patient-centered care through advanced imaging and therapy. Key collaborations include UCLA Health, David Geffen School of Medicine, and UCLA Health Jonsson Comprehensive Cancer Center.
The new clinical cancer research center will support lung and genitourinary cancers, serving as a central hub for seven VA medical centers. The grant aims to improve access to precision oncology trials and patient care for veterans diagnosed at later stages.
A new study suggests that chronological age should be considered when creating treatment plans for men with metastatic hormone-sensitive prostate cancer. Older patients are more likely to experience comorbid conditions and die from causes other than prostate cancer.
A new USC study identified five genes linked to aggressive prostate cancer in people of African descent, including ATM, BRCA2, CHEK2, HOXB13 and PALB2. The researchers developed a method combining genetic risk scores with family history and specific variant presence for personalized monitoring and treatment strategies.
Researchers from Arc Institute, UCSF, and Fred Hutchinson Cancer Center identified PTGES3 as a key regulator of the androgen receptor in prostate cancer. The study found that PTGES3 contributes to tumor growth and suggests it could be a promising new target for treating aggressive prostate cancers.
The European Randomized Study of Screening for Prostate Cancer found that PSA screening can substantially reduce deaths from prostate cancer, with a 13% relative reduction in prostate cancer mortality after 23 years. However, the study also highlights the issue of overdiagnosis associated with PSA screening.
A recent survey conducted by Orlando Health found that over one-third of men (38%) would rather endure stressful situations than discuss their prostate health. The reluctance to address this common issue often leads to delayed diagnosis and treatment, affecting men's quality of life.
Researchers at MD Anderson Cancer Center identified distinct cellular microenvironments in diffuse large B-cell lymphoma tumors, providing a framework to develop therapies that engage the patient's immune system. Additionally, a study found widespread misbeliefs about the cancer risks of alcohol among Americans, highlighting the need f...
A study led by Olaf Merkel and colleagues identified thyroid hormone receptor TRβ as a key driver of prostate cancer growth, with blocking the receptor inhibiting tumour development. The findings offer new perspectives for treating castration-resistant prostate cancer and provide a potential target for new drugs.
UCLA investigators unveil decade-long survival data for immunotherapy in advanced lung cancer and promising results for novel therapies targeting PSMA, DKK1, and FGFR3 in various aggressive cancers. These breakthroughs hold promise for improved treatment outcomes and quality of life for patients with difficult-to-treat diseases.
A clinical trial showed a new drug combination reduced deaths in patients with recurrent prostate cancer after surgery or radiation therapy. The combination of hormone therapy and enzalutamide cut the risk of death by 40%, offering a meaningful treatment option for high-risk patients.
Researchers developed a high-speed whole-body SPECT method to track tumor evolution and personalize prostate cancer treatment. The new approach enabled faster monitoring, allowing for earlier adjustments to treatment plans and improved patient outcomes.
A major international study has identified two enzymes that play a crucial role in helping prostate cancer cells grow and survive. Blocking these enzymes can destabilize the androgen receptor, making tumours more vulnerable to existing therapies.
A UK study of 10 million men found that prostate specific antigen (PSA) testing may not effectively target those most likely to benefit from the test. Many patients are being retested more frequently than recommended, even without symptoms or previous low PSA values.
Paul Boutros, a pioneer in using AI and machine learning to analyze cancer data, is appointed as the new director of the National Cancer Institute-designated cancer center at Sanford Burnham Prebys. The cancer center will leverage computational tools to personalize therapies for cancer patients.